FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Drug Test Anal / Label-free proteomics for discovering biomarker candidates o...
Drug testing and analysis2021; 13(5); 1034-1047; doi: 10.1002/dta.2988

Label-free proteomics for discovering biomarker candidates of RAD140 administration to castrated horses.

Abstract: Selective androgen receptor (AR) modulators (SARMs) are potent anabolic agents with a high potential of misuse in horseracing and equestrian sports. In this study, we applied label-free proteomics to discover plasma protein biomarkers in geldings (castrated horses) after administration with a popular SARM named RAD140. Tryptic peptides were prepared from plasma samples and analyzed by nano-flow ultrahigh-performance liquid chromatography-high-resolution tandem mass spectrometry (nano-UHPLC-HRMS/MS) using data-independent acquisition (DIA) method. Orthogonal projection on latent structure-discriminant analysis (OPLS-DA) has led to the development of a predictive model that could discriminate RAD140-administered samples from control samples and could also correctly classify 18 out of 19 in-training horses as control samples. The model comprises 75 proteins with variable importance in projection (VIP) score above 1. Gene Ontology (GO) enrichment analysis and literature review have identified upregulation of AR-regulated clusterin, and proteins associated with inflammation (haptoglobin, cluster of differentiation 14 [CD14], and inter-alpha-trypsin inhibitor heavy chain 4 [ITIH4]) and erythropoiesis (glycosylphosphatidylinositol-specific phospholipase D1 [GPLD1]) after RAD140 administration. Their changes were confirmed by selected reaction monitoring (SRM) experiments. Similar effects have been reported by the use of androgens and other SARMs. This is the first reported study that describes the use of a proteomic biomarker approach to detect horses that have been administered with RAD140 by applying label-free proteomic profiling of plasma samples. These results support the concept of a biomarker-driven approach to enhance the doping control of RAD140 and potentially other SARMs in the future.
© 2020 John Wiley & Sons, Ltd.
Get Full Text
Publication Date: 2021-01-05 PubMed ID: 33277807DOI: 10.1002/dta.2988Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article presents a study on the use of label-free proteomics to discover plasma protein biomarkers in castrated horses administered with RAD140, a popular selective androgen receptor (SARM). The researchers used this technique to identify plasma proteins that change in response to RAD140 administration, marking a first in exploring such detection methods for doping control in horses.

Research Methodology

  • The researchers conducted the study on geldings which are castrated horses. These horses were administered with a SARM known as RAD140.
  • To discover plasma protein biomarkers, they prepared tryptic peptides from plasma samples from these horses. These peptides were then analyzed through a method known as nano-flow ultrahigh-performance liquid chromatography-high-resolution tandem mass spectrometry (nano-UHPLC-HRMS/MS) that used a data-independent acquisition (DIA) method.
  • The researchers developed a predictive model using OWL-DL (Orthogonal Projection on Latent Structure-Discriminant). This model has been found to be effective in distinguishing samples of horses administered RAD140 from control samples.

Findings

  • The predictive model was made up of 75 proteins that had a variable importance in projection (VIP) score above 1.
  • Through Gene Ontology (GO) enrichment analysis and a review of the existing literature, it was discovered that administration of RAD140 led to the upregulation of AR-regulated clusterin and proteins associated with inflammation and erythropoiesis.
  • Such proteins included haptoglobin, cluster of differentiation 14 (CD14), and inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) that are associated with inflammation and glycosylphosphatidylinositol-specific phospholipase D1 (GPLD1) that is linked to erythropoiesis.
  • The observed changes were further confirmed through selected reaction monitoring (SRM) experiments.

Significance and Application

  • This study marks the first evidence of the use of a proteomic biomarker approach to detect the administration of RAD140 in horses.
  • Such an approach is important in equestrian sports and horseracing where SARMs like RAD140 have high misuse potential as doping agents.
  • The biomarker-driven approach to enhance doping control of RAD140 and potentially other SARMs is supported by this study.

Cite This Article

APA
Cheung HW, Wong KS, To NS, Bond AJ, Farrington AF, Prabhu A, Curl P, Wan TSM, Ho ENM. (2021). Label-free proteomics for discovering biomarker candidates of RAD140 administration to castrated horses. Drug Test Anal, 13(5), 1034-1047. https://doi.org/10.1002/dta.2988

Publication

Drug testing and analysis
ISSN: 1942-7611
NlmUniqueID: 101483449
Country: England
Language: English
Volume: 13
Issue: 5
Pages: 1034-1047

Researcher Affiliations

Cheung, Hiu Wing
  • Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, Hong Kong, China.
Wong, Kin-Sing
  • Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, Hong Kong, China.
To, Ning Sum
  • Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, Hong Kong, China.
Bond, Amanda J
  • Equestrian Affairs, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, Hong Kong, China.
Farrington, Adrian F
  • Department of Veterinary Clinical Services, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, Hong Kong, China.
Prabhu, Anil
  • Department of Veterinary Regulation, Welfare and Biosecurity Policy, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, Hong Kong, China.
Curl, Peter
  • Department of Veterinary Regulation, Welfare and Biosecurity Policy, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, Hong Kong, China.
Wan, Terence S M
  • Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, Hong Kong, China.
Ho, Emmie N M
  • Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, Hong Kong, China.

MeSH Terms

  • Anabolic Agents / administration & dosage
  • Anabolic Agents / chemical synthesis
  • Animals
  • Biomarkers / blood
  • Blood Proteins / analysis
  • Chromatography, High Pressure Liquid / veterinary
  • Doping in Sports
  • Horses / blood
  • Male
  • Nitriles / administration & dosage
  • Nitriles / chemical synthesis
  • Orchiectomy
  • Oxadiazoles / administration & dosage
  • Oxadiazoles / chemical synthesis
  • Proteome
  • Proteomics
  • Reproducibility of Results
  • Substance Abuse Detection / veterinary
  • Tandem Mass Spectrometry / veterinary

References

This article includes 44 references
  1. Bhasin S, Calof OM, Storer TW. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging.. Nat Clin Pract Endocrinol Metab 2006;2(3):146-159.
  2. Buijsman RC, Hermkens PH, van Rijn RD, Stock HT, Teerhuis NM. Non-steroidal steroid receptor modulators.. Curr Med Chem 2005;12(9):1017-1075.
  3. Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT. Selective androgen receptor modulators in preclinical and clinical development.. Nucl Recept Signal 2008;6:e010.1-26.
  4. Gao W, Dalton JT. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs).. Drug Discov Today 2007;12(5-6):241-248.
  5. Kilbourne EJ, Moore WJ, Freedman LP, Nagpal S. Selective androgen receptor modulators for frailty and osteoporosis.. Curr Opin Investig Drugs (London, England: 2000) 2007;8(10):821-829.
  6. Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical composition and labeling of substances marketed as selective androgen receptor modulators and sold via the Internet.. JAMA 2017;318(20):2004-2010.
  7. Flores JE, Chitturi S, Walker S. Drug-induced liver injury by selective androgenic receptor modulators.. Hepatol Commun 2020;4(3):450-452.
  8. World Anti-Doping Agency. Prohibited list.. 2020.
  9. International Federation of Horseracing Authorities. International agreement on breeding, racing and wagering and appendixes.. 2020.
  10. Fédération Équestre Internationale. Equine prohibited substances list.. 2020.
  11. Thevis M, Piper T, Beuck S, Geyer H, Schanzer W. Expanding sports drug testing assays: mass spectrometric characterization of the selective androgen receptor modulator drug candidates RAD140 and ACP-105.. Rapid Commun Mass Spectrom: RCM 2013;27(11):1173-1182.
  12. Thevis M, Schanzer W. Detection of SARMs in doping control analysis.. Mol Cell Endocrinol 2018;464:34-45.
  13. Thevis M, Volmer DA. Mass spectrometric studies on selective androgen receptor modulators (SARMs) using electron ionization and electrospray ionization/collision-induced dissociation.. Eur J Mass Spectrom (Chichester, Eng) 2018;24(1):145-156.
  14. Reichel C. OMICS-strategies and methods in the fight against doping.. Forensic Sci Int 2011;213(1-3):20-34.
  15. Joré C, Loup B, Garcia P. Liquid chromatography-high resolution mass spectrometry-based metabolomic approach for the detection of continuous erythropoiesis receptor activator effects in horse doping control.. J Chromatogr A 2017;1521:90-99.
  16. Riedmaier I, Becker C, Pfaffl MW, Meyer HH. The use of omic technologies for biomarker development to trace functions of anabolic agents.. J Chromatogr A 2009;1216(46):8192-8199.
  17. Wong KS, Cheung HW, Choi TLS. Label-free proteomics for discovering biomarker candidates for controlling krypton misuse in castrated horses (geldings).. J Proteome Res 2020;19(3):1196-1208.
  18. Cox HD, Lopes F, Woldemariam GA. Interlaboratory agreement of insulin-like growth factor 1 concentrations measured by mass spectrometry.. Clin Chem 2014;60(3):541-548.
  19. Robinson N, Sottas PE, Schumacher YO. The athlete biological passport: how to personalize anti-doping testing across an athlete's career?. Med Sport Sci 2017;62:107-118.
  20. Bruderer R, Bernhardt OM, Gandhi T. Optimization of experimental parameters in data-independent mass spectrometry significantly increases depth and reproducibility of results.. Mol Cell Proteomics: MCP 2017;16(12):2296-2309.
  21. Xuan Y, Muntel J, Berger ST, Huhme AFR, Steen H, Moehring T. Overcoming the challenges in data independent acquisition (DIA) via high resolution accurate mass Orbitrap based mass spectrometer.. Therm Sci Poster Note 2015;64405.1-3.
  22. Collins BC, Hunter CL, Liu Y. Multi-laboratory assessment of reproducibility, qualitative and quantitative performance of SWATH-mass spectrometry.. Nat Commun 2017;8(1):291-302.
  23. Geyer PE, Kulak NA, Pichler G, Holdt LM, Teupser D, Mann M. Plasma proteome profiling to assess human health and disease.. Cell Systems 2016;2(3):185-195.
  24. Gao Y, Wang X, Sang Z. Quantitative proteomics by SWATH-MS reveals sophisticated metabolic reprogramming in hepatocellular carcinoma tissues.. Sci Rep 2017;7(1):45913.45913-45924.
  25. Nguyen EV, Centenera MM, Moldovan M. Identification of novel response and predictive biomarkers to Hsp90 inhibitors through proteomic profiling of patient-derived prostate tumor explants.. Mol Cell Proteomics: MCP 2018;17(8):1470-1486.
  26. Miller CP, Shomali M, Lyttle CR. Design, synthesis, and preclinical characterization of the selective androgen receptor modulator (SARM) RAD140.. ACS Med Chem Lett 2011;2(2):124-129.
  27. Callister SJ, Barry RC, Adkins JN. Normalization approaches for removing systematic biases associated with mass spectrometry and label-free proteomics.. J Proteome Res 2006;5(2):277-286.
  28. Reiter L, Rinner O, Picotti P. mProphet: automated data processing and statistical validation for large-scale SRM experiments.. Nat Methods 2011;8(5):430-435.
  29. Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics.. J Proteome Res 2007;6(2):469-479.
  30. Eriksson L, Trygg J, Wold S. CV-ANOVA for significance testing of PLS and OPLS models.. J Chemometr 2008;22(11-12):594-600.
  31. Wiklund S, Johansson E, Sjostrom L. Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models.. Anal Chem 2008;80(1):115-122.
  32. Huang d W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.. Nat Protoc 2009;4(1):44-57.
  33. Gruys E, Toussaint MJ, Niewold TA, Koopmans SJ. Acute phase reaction and acute phase proteins.. J Zhejiang Univ Sci B 2005;6(11):1045-1056.
  34. Barbosa J, Seal US, Doe RP. Effects of anabolic steroids on haptoglobin, orosomucoid, plasminogen, fibrinogen, transferrin, ceruloplasmin, alpha-1-antitrypsin, beta-glucuronidase and total serum proteins.. J Clin Endocrinol Metab 1971;33(3):388-398.
  35. Cochrane DR, Wang Z, Muramaki M, Gleave ME, Nelson CC. Differential regulation of clusterin and its isoforms by androgens in prostate cells.. J Biol Chem 2007;282(4):2278-2287.
  36. Matsumoto H, Yamamoto Y, Shiota M. Cotargeting androgen receptor and clusterin delays castrate-resistant prostate cancer progression by inhibiting adaptive stress response and AR stability.. Cancer Res 2013;73(16):5206-5217.
  37. Garcia-Aranda M, Serrano A, Redondo M. Regulation of clusterin gene expression.. Curr Protein Pept Sci 2018;19(6):612-622.
  38. Naponelli V, Bettuzzi S. Clusterin.. 2018:341-349.
  39. Delev D, Rangelov A, Ubenova D, Kostadinov I, Zlatanova H, Kostadinova I. Mechanism of action of androgens on erythropoiesis-a review.. Int J Pharm Clin Res 2016;8(11):1489-1492.
  40. Heath KE, Argente J, Barrios V. Primary acid-labile subunit deficiency due to recessive IGFALS mutations results in postnatal growth deficit associated with low circulating insulin growth factor (IGF)-I, IGF binding protein-3 levels, and hyperinsulinemia.. J Clin Endocrinol Metab 2008;93(5):1616-1624.
  41. Cutler C, Viljanto M, Hincks P, Habershon-Butcher J, Muir T, Biddle S. Investigation of the metabolism of the selective androgen receptor modulator LGD-4033 in equine urine, plasma and hair following oral administration.. Drug Test Anal 2020;12(2):247-260.
  42. Gray B, Viljanto M, Menzies E, Vanhaecke L. Detection of prohibited substances in equine hair by ultra-high performance liquid chromatography-triple quadrupole mass spectrometry-application to doping control samples.. Drug Test Anal 2018;10(7):1050-1060.
  43. Kintz P, Ameline A, Gheddar L, Raul J-S. LGD-4033, S-4 and MK-2866-testing for SARMs in hair: about 2 doping cases.. Toxicol Anal Clin 2019;31(1):56-63.
  44. Bruderer R, Bernhardt OM, Gandhi T, Reiter L. High-precision iRT prediction in the targeted analysis of data-independent acquisition and its impact on identification and quantitation.. Proteomics 2016;16(15-16):2246-2256.

Citations

This article has been cited 2 times.
  1. Rooney MF, Neto NGB, Monaghan MG, Hill EW, Porter RK. Conditionally immortalised equine skeletal muscle cell lines for in vitro analysis. Biochem Biophys Rep 2023 Mar;33:101391.
    doi: 10.1016/j.bbrep.2022.101391pubmed: 36504704google scholar: lookup
  2. Peerapen P, Boonmark W, Putpeerawit P, Sassanarakkit S, Thongboonkerd V. Proteomic and computational analyses followed by functional validation of protective effects of trigonelline against calcium oxalate-induced renal cell deteriorations. Comput Struct Biotechnol J 2023;21:5851-5867.
    doi: 10.1016/j.csbj.2023.11.036pubmed: 38074474google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.